You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The infectious disease testing firm has developed a sequencing-based coronavirus assay, which it plans to commercialize through its sister firm BioID Genomics.
The Boston-based firm is developing a bacterial diagnostic platform to detect antibiotic resistance and help guide antibiotic treatment in hospitals.
The Boston-based startup will use the funding to flesh out its diagnostic platform to detect antibiotic-resistant bacterial infections within a clinically relevant timeframe.
The firms are developing clinical and RUO workflows that use NGS for pathogen identification and will comarket IDbyDNA's Explify data platform.
Atrin will use Predictive's GenDB databases and women's health biobank to study germline mutations in DNA damage and response inhibitor pathways.
In seven years, the public variant classification database has steadily become a resource that labs are submitting to and that genetics experts are consulting.
The Eudamed database is an integral part of the new Medical Device and IVD Regulations that go into effect in 2020 and 2022.
The firms aim to combine PerkinElmer 's Ordered Data Interpretation Network and FDNA's Face2Gene facial analysis software to target emerging markets.
New funding will support assay development and lab space to offer test services, and ultimately a test kit using the firm's resistance database.
By leveraging HealthShare's Informatic Exchange solution, Rhodes Group will create a longitudinal, standardized data repository across TriCore's laboratories.